<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04213794</url>
  </required_header>
  <id_info>
    <org_study_id>MC1947</org_study_id>
    <secondary_id>NCI-2019-08650</secondary_id>
    <secondary_id>MC1947</secondary_id>
    <secondary_id>P30CA015083</secondary_id>
    <nct_id>NCT04213794</nct_id>
  </id_info>
  <brief_title>Heated Intra-peritoneal Chemotherapy With Doxorubicin and Cisplatin for the Treatment of Resectable, Refractory, or Recurrent Rhabdomyosarcoma in Pediatric Patients, T.O.A.S.T. I.T. Study</brief_title>
  <official_title>A Prospective Study of Heated Intra-Peritoneal Chemotherapy (H.I.P.E.C.) With Doxorubicin and Cisplatin in Pediatric Patients With Rhabdomyosarcoma. The TOAST IT Trial (Trial Of Adjuvant Surgical Treatment With Intraperitoneal Chemotherapy)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This early phase I trial studies how well heated intra-peritoneal chemotherapy with&#xD;
      doxorubicin and cisplatin work for the treatment of abdominal or pelvic tumors that can be&#xD;
      removed by surgery (resectable), does not respond to treatment (refractory), or has come back&#xD;
      (recurrent). Heated intra-peritoneal chemotherapy is a procedure performed in combination&#xD;
      with abdominal surgery for cancer that has spread to the abdomen. It involves the infusion of&#xD;
      a heated chemotherapy solution that circulates into the abdominal cavity. Drugs used in&#xD;
      chemotherapy, such as doxorubicin and cisplatin, work in different ways to stop the growth of&#xD;
      tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them&#xD;
      from spreading. Heating a chemotherapy solution and infusing it directly into the abdomen may&#xD;
      kill more cells.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. To assess the feasibility of heated intra-peritoneal chemotherapy (HIPEC) with doxorubicin&#xD;
      (DOXO) and cisplatin (CDDP) after surgical resection of pediatric pelvic and abdominal&#xD;
      rhabdomyosarcoma tumors.&#xD;
&#xD;
      II. To assess morbidity, hospital length of stay and peri-operative mortality outcomes for&#xD;
      pediatric patients with intraperitoneal rhabdomyosarcoma undergoing hyperthermic&#xD;
      intraperitoneal chemotherapy.&#xD;
&#xD;
      SECONDARY OBJECTIVE:&#xD;
&#xD;
      I. Evaluate disease recurrence patterns: locoregional versus distant.&#xD;
&#xD;
      OUTLINE:&#xD;
&#xD;
      Patients undergo cytoreduction. Patients also undergo HIPEC over 60 minutes consisting of&#xD;
      doxorubicin and cisplatin. Patients then receive sodium thiosulfate intravenously (IV) over&#xD;
      12 hours.&#xD;
&#xD;
      After completion of the study treatment, patients are followed every 6 months for 5 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 1, 2019</start_date>
  <completion_date type="Anticipated">January 30, 2025</completion_date>
  <primary_completion_date type="Anticipated">January 30, 2025</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of adverse events of cytoreductive surgery (CRS) with heated intra-peritoneal chemotherapy (HIPEC) in this patient population</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>To assess the feasibility of heated intra-peritoneal chemotherapy (HIPEC) with doxorubicin (DOXO) and cisplatin (CDDP) after surgical resection of pediatric pelvic and abdominal rhabdomyosarcoma.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>From the time of diagnosis of cancer up, assessed to 5 years</time_frame>
    <description>Will be estimated using the Kaplan-Meier method. Patterns of tumor recurrence and survival will be assessed by reviewing routine surveillance imaging. Patient contact may be contacted by telephone.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease-free survival (DFS)</measure>
    <time_frame>From the time of diagnosis of cancer up to 5 years</time_frame>
    <description>Patterns of tumor recurrence and survival will be assessed by reviewing routine surveillance imaging. Patient contact may be contacted by telephone.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peritoneal-free recurrence</measure>
    <time_frame>From the time of diagnosis of cancer up to 5 years</time_frame>
    <description>Patterns of tumor recurrence and survival will be assessed by reviewing routine surveillance imaging. Patient contact may be contacted by telephone.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of morbidity</measure>
    <time_frame>30, 60, and, 90 days post-HIPEC procedure</time_frame>
    <description>Will be measured using the Clavien Dindo scale and the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 5.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of mortality</measure>
    <time_frame>30 days post-HIPEC procedure</time_frame>
    <description>Will be tracked using NCI CTCAE version 5.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital length of stay</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Will be tracked using NCI CTCAE version 5.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival (PFS)</measure>
    <time_frame>From the time protocol treatment is initiated, assessed up to 5 years</time_frame>
    <description>The PFS is defined as the time between initiation of protocol treatment and the first occurrence of disease. It will be defined radiologically.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">43</enrollment>
  <condition>Malignant Abdominal Neoplasm</condition>
  <condition>Malignant Pelvic Neoplasm</condition>
  <condition>Recurrent Rhabdomyosarcoma</condition>
  <condition>Recurrent Sarcoma</condition>
  <condition>Refractory Rhabdomyosarcoma</condition>
  <condition>Refractory Sarcoma</condition>
  <condition>Resectable Sarcoma</condition>
  <arm_group>
    <arm_group_label>Treatment (cytoreduction, HIPEC)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients undergo cytoreduction. Patients also undergo HIPEC over 60 minutes consisting of doxorubicin and cisplatin. Patients then receive sodium thiosulfate IV over 12 hours.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>Undergo HIPEC with doxorubicin and cisplatin</description>
    <arm_group_label>Treatment (cytoreduction, HIPEC)</arm_group_label>
    <other_name>Abiplatin</other_name>
    <other_name>Blastolem</other_name>
    <other_name>Briplatin</other_name>
    <other_name>CDDP</other_name>
    <other_name>Cis-diammine-dichloroplatinum</other_name>
    <other_name>Cis-diamminedichloridoplatinum</other_name>
    <other_name>Cis-diamminedichloro Platinum (II)</other_name>
    <other_name>Cis-diamminedichloroplatinum</other_name>
    <other_name>Cis-dichloroammine Platinum (II)</other_name>
    <other_name>Cis-platinous Diamine Dichloride</other_name>
    <other_name>Cis-platinum</other_name>
    <other_name>Cis-platinum II</other_name>
    <other_name>Cis-platinum II Diamine Dichloride</other_name>
    <other_name>Cismaplat</other_name>
    <other_name>Cisplatina</other_name>
    <other_name>Cisplatinum</other_name>
    <other_name>Cisplatyl</other_name>
    <other_name>Citoplatino</other_name>
    <other_name>Citosin</other_name>
    <other_name>Cysplatyna</other_name>
    <other_name>DDP</other_name>
    <other_name>Lederplatin</other_name>
    <other_name>Metaplatin</other_name>
    <other_name>Neoplatin</other_name>
    <other_name>Peyrone''s Chloride</other_name>
    <other_name>Peyrone''s Salt</other_name>
    <other_name>Placis</other_name>
    <other_name>Plastistil</other_name>
    <other_name>Platamine</other_name>
    <other_name>Platiblastin</other_name>
    <other_name>Platiblastin-S</other_name>
    <other_name>Platinex</other_name>
    <other_name>Platinol</other_name>
    <other_name>Platinol- AQ</other_name>
    <other_name>Platinol-AQ</other_name>
    <other_name>Platinol-AQ VHA Plus</other_name>
    <other_name>Platinoxan</other_name>
    <other_name>Platinum</other_name>
    <other_name>Platinum Diamminodichloride</other_name>
    <other_name>Platiran</other_name>
    <other_name>Platistin</other_name>
    <other_name>Platosin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Cytoreductive Surgery</intervention_name>
    <description>Undergo cytoreduction</description>
    <arm_group_label>Treatment (cytoreduction, HIPEC)</arm_group_label>
    <other_name>Cytoreduction</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxorubicin</intervention_name>
    <description>Undergo HIPEC with doxorubicin and cisplatin</description>
    <arm_group_label>Treatment (cytoreduction, HIPEC)</arm_group_label>
    <other_name>Adriablastin</other_name>
    <other_name>Hydroxydaunomycin</other_name>
    <other_name>Hydroxyl Daunorubicin</other_name>
    <other_name>Hydroxyldaunorubicin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hyperthermic Intraperitoneal Chemotherapy</intervention_name>
    <description>Undergo HIPEC with doxorubicin and cisplatin</description>
    <arm_group_label>Treatment (cytoreduction, HIPEC)</arm_group_label>
    <other_name>HIPEC</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sodium Thiosulfate</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (cytoreduction, HIPEC)</arm_group_label>
    <other_name>Cyanide Antidote Package</other_name>
    <other_name>Disodium thiosulfate</other_name>
    <other_name>S-Hydril</other_name>
    <other_name>Sodium Hyposulfate</other_name>
    <other_name>Sodium Thiosulfate Pentahydrate</other_name>
    <other_name>Sodium Thiosulphate</other_name>
    <other_name>Sodothiol</other_name>
    <other_name>Thiosulfate, Sodium, Pentahydrate</other_name>
    <other_name>Thiosulfuric Acid Disodium Salt</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients must have resectable, primary refractory or recurrent intra-abdominal or&#xD;
             pelvic Rhabdomyosarcoma based on imaging studies with measurable disease (&gt;= 1 cm in 2&#xD;
             perpendicular planes), or primary tumor with peritoneal implants in whom no known&#xD;
             other curative treatment exists, and/or patients not on up-front clinical trial&#xD;
&#xD;
          -  Evidence of macroscopic or microscopic intra-peritoneal seeding (separate from the&#xD;
             primary tumor) identified at the time of exploratory surgery with or without primary&#xD;
             tumor resection&#xD;
&#xD;
          -  Peritoneal cancer index (PCI) =&lt; 20 and surgeons deem high likelihood of complete&#xD;
             residual tumor stage R0 (R0) resection&#xD;
&#xD;
          -  No evidence of distant metastases at the time of enrollment&#xD;
&#xD;
          -  Histologies to be considered include: rhabdomyosarcoma,&#xD;
&#xD;
          -  Patients may be included in the study independent of the regimen of previous surgical,&#xD;
             radiation, or chemotherapy treatments administered. Given the increased risk of&#xD;
             entero-cutaneous fistulae observed in patients treated with HIPEC AFTER radiation&#xD;
             therapy, patients may be excluded based on the assessment of risk by our radiation&#xD;
             oncology team&#xD;
&#xD;
          -  Karnofsky / Lansky performance score of &gt;= 40 or Eastern Cooperative Oncology Group&#xD;
             (ECOG) performance score of 3 or less&#xD;
&#xD;
          -  Platelet count &gt;= 50,000 (independent of transfusion) (performed no later than 14 days&#xD;
             before surgery)&#xD;
&#xD;
          -  Prothrombin and partial thromboplastin times =&lt; 1.2 X normal (performed no later than&#xD;
             14 days before surgery)&#xD;
&#xD;
          -  Total bilirubin =&lt; 2 X normal (performed no later than 14 days before surgery)&#xD;
&#xD;
          -  Serum glutamic-oxaloacetic transaminase (SGOT) =&lt; 2 X normal (performed no later than&#xD;
             14 days before surgery)&#xD;
&#xD;
          -  Serum glutamate pyruvate transaminase (SGPT) =&lt; 2 X normal (performed no later than 14&#xD;
             days before surgery)&#xD;
&#xD;
          -  Lactate dehydrogenase (LDH) =&lt; 2 X normal (performed no later than 14 days before&#xD;
             surgery)&#xD;
&#xD;
          -  Alkaline phosphatase =&lt; 2 X normal (performed no later than 14 days before surgery)&#xD;
&#xD;
          -  Neutrophil count &gt;= 750 (performed no later than 14 days before surgery)&#xD;
&#xD;
          -  Patients must have adequate renal function defined as creatinine clearance (performed&#xD;
             no later than 14 days before surgery) or radioisotope GFR (glomerular filtration rate)&#xD;
             &gt;= 70 mL/min/1.73 m^2 or a serum creatinine based on age/gender less than the&#xD;
             following values:&#xD;
&#xD;
               -  1 to &lt; 2 years 0.6mg/dL for both males and females&#xD;
&#xD;
               -  2 to &lt; 6 years 0.8mg/dL for both males and females&#xD;
&#xD;
               -  6 to &lt;10 years 1.0mg/dL for both males and females&#xD;
&#xD;
          -  A signed informed consent form (and assent form when appropriate) approved by the Mayo&#xD;
             Clinic (Institutional Review Board [IRB]) will be required for patient enrollment into&#xD;
             the study. Patients must be able to read and understand the informed consent document&#xD;
             and must sign the informed consent indicating that they are aware of the&#xD;
             investigational nature of this study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Females who are pregnant or breast-feeding during the study period will be excluded&#xD;
&#xD;
          -  Distant metastatic disease not limited to peritoneum:&#xD;
&#xD;
               -  Solid organ metastases (liver, central nervous system, lung)&#xD;
&#xD;
               -  Known bone marrow involvement&#xD;
&#xD;
          -  No critical cumulative dose of previous chemotherapy (total anthracycline dose not &gt;=&#xD;
             435 mg / m^2)&#xD;
&#xD;
          -  Prior HIPEC within 3 months&#xD;
&#xD;
          -  Patients with an active infection requiring treatment or having an unexplained febrile&#xD;
             illness (Tmax &gt; 99.5 Fahrenheit [F]), patients with known immune deficiency disorder&#xD;
             or known human immunodeficiency virus infection&#xD;
&#xD;
          -  Patients must not have any systemic illness which precludes them from being an&#xD;
             operative candidate as determined by anesthesia preoperative evaluation. This includes&#xD;
             but is not limited to, sepsis, liver failure, renal failure, cardiovascular failure,&#xD;
             pulmonary failure&#xD;
&#xD;
          -  Subjects deemed unable to comply with study and/or follow-up procedures&#xD;
&#xD;
          -  Subjects with a known hypersensitivity to protocol systemic chemotherapy that was&#xD;
             life-threatening, required hospitalization or prolongation of existing&#xD;
             hospitalization, or resulted in persistent or significant disability or incapacitation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>25 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Patricio C Gargollo</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Referral Office</last_name>
      <phone>855-776-0015</phone>
      <email>mayocliniccancerstudies@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>Patricio C. Gargollo</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.mayo.edu/research/clinical-trials</url>
    <description>Mayo Clinic Clinical Trials</description>
  </link>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>December 27, 2019</study_first_submitted>
  <study_first_submitted_qc>December 27, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 30, 2019</study_first_posted>
  <last_update_submitted>January 27, 2021</last_update_submitted>
  <last_update_submitted_qc>January 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Patricio C. Gargollo</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Rhabdomyosarcoma</keyword>
  <keyword>HIPEC</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Sarcoma</mesh_term>
    <mesh_term>Rhabdomyosarcoma</mesh_term>
    <mesh_term>Abdominal Neoplasms</mesh_term>
    <mesh_term>Pelvic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sodium thiosulfate</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Daunorubicin</mesh_term>
    <mesh_term>Antidotes</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

